Aflac Inc is not a strong buy for a beginner investor with a long-term strategy at this time. While the stock shows some bullish technical indicators, the financial performance is declining, and analyst sentiment is mixed to negative. Additionally, there are no strong positive catalysts or proprietary trading signals to support immediate action.
The stock shows bullish technical indicators with MACD positively expanding above 0, RSI at 70.941 in the neutral zone, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). The current price of $113.71 is above the pivot point of $111.613, with resistance levels at $113.462 and $114.604.

Hedge funds are significantly increasing their positions in Aflac, with a 695012.50% increase in buying over the last quarter. Technical indicators are bullish, and the stock has a 7.55% chance of increasing in the next month.
Additionally, guidance indicates challenges in Japan and limited growth in the U.S.
In Q4 2025, Aflac's revenue dropped by 9.94% YoY to $4.87 billion, net income declined by 27.50% YoY to $1.38 billion, and EPS fell by 22.81% YoY to $2.64. While gross margin remained stable, the overall financial performance reflects significant challenges.
Analyst sentiment is mixed to negative. Recent updates include Mizuho lowering the price target to $102 with an Underperform rating, UBS lowering the price target to $114 with a Neutral rating, and Keefe Bruyette raising the price target to $115 with a Market Perform rating. Analysts highlight challenges in the life insurance sector, including competition, economic uncertainty, and limited profitability potential.